At a glance
- Originator Bristol-Myers Squibb
- Class Anti-inflammatories; Antiasthmatics; Aziridines; Piperazines
- Mechanism of Action Tryptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic asthma
Most Recent Events
- 18 Dec 2003 No development reported - Preclinical for Allergic asthma in USA (unspecified route)
- 19 Apr 2001 New profile
- 19 Apr 2001 Preclinical development for Allergic asthma in USA (Unknown route)